Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 9.3 years: an updated integrated safety analysis

Bibliographic Details
Main Authors:	Taylor, P, Takeuchi, T, Burmester, G, Durez, P, Smolen, J, Deberdt, W, Zhong, J, Teres, JR, Bello, N, Winthrop, K, Pope, J
Format:	Conference item
Language:	English
Published:	Journal of Rheumatology 2022

Similar Items

Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database
by: Taylor, P, et al.
Published: (2021)

Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis
by: Weinblatt, M, et al.
Published: (2017)

Cardiovascular safety - Update from up to 6 years of treatment with baricitinib in rheumatoid arthritis clinical trials
by: Weinblatt, M, et al.
Published: (2018)

Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis
by: Taylor, P, et al.
Published: (2019)

Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib
by: Robert Harrington, et al.
Published: (2023-10-01)

Efficacy and safety of switching from adalimumab to baricitinib: Phase 3 data in patients with rheumatoid arthritis
by: Taylor, P, et al.
Published: (2016)

Efficacy and safety of switching from adalimumab to baricitinib: phase 3 data in patients with rheumatoid arthritis
by: Taylor, P, et al.
Published: (2017)

Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis
by: Naoki Iwamoto, et al.
Published: (2021-07-01)

Baricitinib for the treatment of rheumatoid arthritis
by: Ivan Urits, et al.
Published: (2020-12-01)

Assessment of pain improvement in rheumatoid arthritis patients treated with baricitinib, who were inadequate responders to methotrexate and tumor necrosis factor inhibitors
by: Taylor, P, et al.
Published: (2019)

Baricitinib versus placebo or adalimumab in rheumatoid arthritis
by: Taylor, P, et al.
Published: (2017)

Baricitinib: Early vs. delayed start in patients with rheumatoid arthritis
by: Taylor, P, et al.
Published: (2018)

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate.
by: Keystone, E, et al.
Published: (2015)

Baricitinib exposure during pregnancy in rheumatoid arthritis
by: Giulia Costanzo, et al.
Published: (2020-01-01)

Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis—a comprehensive review
by: Paul Emery, et al.
Published: (2021-01-01)

Safety and efficacy of baricitinib through 128 weeks in an open-label, longterm extension study in patients with rheumatoid arthritis
by: Keystone, EC, et al.
Published: (2017)

Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: Results from a long-term study
by: Smolen, JS, et al.
Published: (2020)

Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study
by: Smolen, JS, et al.
Published: (2020)

Summary of indirect comparison to evaluate efficacy of baricitinib with targeted synthetic and biologic disease anti-rheumatic drugs in patients with rheumatoid arthritis
by: Emery, P, et al.
Published: (2019)

Rapid and sustained pain improvement in rheumatoid arthritis patients treated with baricitinib compared to adalimumab or placebo
by: Taylor, P, et al.
Published: (2017)

A JAK inhibitor for treatment of rheumatoid arthritis: the baricitinib experience
by: Taylor, PC, et al.
Published: (2023)

Association between baseline haemoglobin levels and radiographic joint damage progression in patients with rheumatoid arthritis treated with baricitinib or standard of care
by: Moeller, B, et al.
Published: (2019)

A review of safety outcomes from clinical trials of baricitinib in rheumatology, dermatology and COVID-19
by: Bieber, T, et al.
Published: (2022)

Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis
by: Paul Emery, et al.
Published: (2020-05-01)

Efficacy and safety of switching from adalimumab to baricitinib: long-term data from phase 3 extension study in patients with rheumatoid arthritis
by: Weinblatt, M, et al.
Published: (2018)

A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience
by: Peter C. Taylor, et al.
Published: (2023-07-01)

New alternative in the treatment of rheumatoid arthritis: clinical utility of baricitinib
by: Kawalec P, et al.
Published: (2019-02-01)

Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy
by: Taylor, P, et al.
Published: (2022)

Safety and Effectiveness of Baricitinib in Chinese Patients with Moderate-to-Severe Rheumatoid Arthritis: 24-Week Results from a Post-Marketing Safety Study
by: Chan-yuan Wu, et al.
Published: (2023-09-01)

Correction to: Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis
by: Paul Emery, et al.
Published: (2020-07-01)

Effect of baricitinib and adalimumab in reducing pain and improving function in patients with rheumatoid arthritis in low disease activity: exploratory analyses from RA-BEAM
by: Fautrel, B, et al.
Published: (2019)

Rapid and concurrent improvements in patient-reported outcomes of rheumatoid arthritis with baricitinib in RA-BEAM
by: Strand, V, et al.
Published: (2021)

Tofacitinib and Baricitinib in Type 2 Diabetic Patients with Rheumatoid Arthritis
by: Cristina Martinez-Molina, et al.
Published: (2024-02-01)

Problems of pain and quality of life in rheumatoid arthritis: focus on baricitinib
by: A. E. Karateev
Published: (2020-09-01)

Patient disease trajectories in baricitinib-treated patients with rheumatoid arthritis and inadequate response to methotrexate
by: Taylor, P, et al.
Published: (2019)

Characterization and changes of lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis: an integrated analysis
by: Tanaka, Y, et al.
Published: (2018)

Safety of rituximab in rheumatoid arthritis
by: F. Atzeni, et al.
Published: (2011-06-01)

Baricitinib safety for events of special interest in populations at risk: analysis from randomised trial data across rheumatologic and dermatologic indications
by: Taylor, PC, et al.
Published: (2023)

Pain reduction in rheumatoid arthritis patients who use opioids: a post hoc analysis of phase 3 trials of baricitinib
by: Pope, JE, et al.
Published: (2021)

Patient disease trajectories in rheumatoid arthritis patients treated with baricitinib 4-mg in 4 phase 3 clinical studies
by: Taylor, PC, et al.
Published: (2023)